Researchers identified a widespread genetic heart risk factor that standard cholesterol tests routinely miss. In a study of over 20,000 people, very high levels of lipoprotein(a), or Lp(a), correlated with substantially increased risk of stroke and cardiovascular death.
Lp(a) is an inherited cholesterol-related particle that the body produces naturally. Unlike LDL cholesterol, which doctors actively screen for and patients can modify through diet and exercise, Lp(a) levels remain largely fixed by genetics. Most people with dangerously high Lp(a) have no idea they carry the risk.
The study found that approximately one in five people may carry elevated Lp(a) levels. Those with very high concentrations faced notably greater odds of major cardiovascular events, including stroke and heart-related death. The findings underscore a critical gap in standard cardiovascular screening.
A simple blood test can detect Lp(a) levels, yet mainstream cholesterol panels do not routinely measure it. This creates a scenario where millions of people walk around with unidentified genetic predisposition to heart disease and stroke. The research suggests broadening screening protocols to include Lp(a) testing could identify people who need aggressive preventive treatment.
The discovery carries particular weight because Lp(a) cannot be addressed through lifestyle modifications alone. People with high levels cannot simply exercise more or eat better to lower their Lp(a). Instead, doctors must consider pharmaceutical interventions. Several drugs show promise in reducing Lp(a), including PCSK9 inhibitors and emerging therapies specifically designed to target this particle.
The study's scale and focus on real-world cardiovascular outcomes strengthen the evidence for why Lp(a) screening matters. Rather than relying solely on traditional risk factors like LDL cholesterol and blood pressure,